Introduction
============

Nitric oxide production by activated macrophages following infection may play a physiological role in the host defense mechanism due to its antimicrobial activity \[[@B1],[@B2]\]. However, sustained and excessive production of NO in severe infection such as sepsis has been implicated in the pathogenesis of septic shock \[[@B3],[@B4],[@B5]\]. Septic shock is characterized by a hyperdynamic state (hypotension, tachycardia, normal or increased cardiac output associated with low systemic vascular resistance), an impairment of tissue perfusion, and hyporesponsiveness to vasoconstrictors \[[@B6]\]. Nitric oxide is produced by three distinct isoenzymes termed NO synthases (NOS): brain and endothelial constitutive NOS (cNOS), and inducible NOS (iNOS). Nitric oxide synthesized by endothelial cNOS is involved in the regulation of basal vascular tone and anti-thrombotic effect by inhibiting platelet aggregation and leukocyte adhesion to the endothelial surface \[[@B1]\]. Excess production of NO by iNOS, stimulated by bacterial lipopolysaccharide (LPS) and several cytokines, may contribute to the cardiovascular dysfunction seen in septic shock \[[@B3],[@B4],[@B5]\].

Several strategies can be used to reduce NO activity during septic shock. L-arginine analogues, such as N^G^-monomethyl-L-arginine (L-NMMA), N^G^-nitro-L-arginine (L-NNA), and N^G^-nitro-L-arginine methyl ester (L-NAME), are non-selective inhibitors for cNOS and iNOS \[[@B1],[@B2]\]. Although these analogues increase blood pressure in septic shock models, they show various deleterious effects, such as decreasing cardiac output, oxygen delivery and metabolic acidosis \[[@B4],[@B5],[@B7]\], possibly due to the non-selective inhibition of endothelial cNOS as well as iNOS. To circumvent these deleterious effects by non-selective NOS inhibitors, relatively selective inhibitors for iNOS, such as aminoguanidine \[[@B8],[@B9]\] and S-methylisothiourea \[[@B10]\], have been developed and studied in septic shock models. Other investigators have tested methylene blue, an inhibitor of soluble guanylate cyclase, which blocks the NO-mediated formation of cyclic guanosine monophosphate (cGMP), a second messenger for vasorelaxation in patients with septic shock \[[@B11]\].

Recently, Akaike *et al* \[[@B12]\] have reported that a nitronyl nitroxide compound, 2-phenyl-4, 4, 5, 5-tetramethylimidazoline-1-oxyl-3-oxide (PTIO) derivative, reacts with NO to generate NO~2~ and 2-phenyl-4, 4, 5, 5-tetramethylimidazoline-1-oxyl (PTI) derivative in a stoichiometric manner. Carboxy-PTIO, a water soluble derivative, has been shown to attenuate hypotension and renal dysfunction in LPS-treated rat models \[[@B13]\]. However, few studies have dealt with the detailed hemodynamic or metabolic effects of the novel NO scavenger in a septic shock dog model. In order to assess the therapeutic potential of carboxy-PTIO in human septic shock, our study was designed to examine the effects of carboxy-PTIO on hemodynamic and blood gas variables in LPS-induced septic shock dogs.

Materials and methods
=====================

Surgical preparation
--------------------

The study was approved by the Institutional Review Board for the care of animal subjects, and the care and handling of the animals was in accord with National Institutes of Health guidelines. Twenty mongrel dogs, 12.6 ± 0.7 kg, were studied. The dogs were anesthetized for intubation with intravenous administration of pentobarbital (20 mg/kg), and connected to a ventilator. The inspired oxygen fraction was maintained at 0.3, and the ventilator rate and tidal volume were adjusted to obtain a normal arterial pH ad PCO~2~ using a pH/blood gas analyser (IL 1306A, Instrumentation Laboratory, Lexington, MA, USA). A catheter was inserted into the femoral vein and Ringer lactate solution (10 ml/kg/h) and pentobarbital (4 mg/kg/h) were administered throughout the study period. A pulmonary artery catheter (93A-141-7F, Baxter Healthcare Corp, Santa Ana, CA, USA) was inserted through the jugular vein. Another catheter was cannulated into the femoral artery for continuous measurement of systemic arterial pressure, and intermittent arterial blood sampling. Heart rate was monitored by electrocardiogram. After surgical preparation, the dogs were allowed to stabilize for 1 h.

LPS protocol
------------

The dogs were divided into two experimental groups: in the LPS group (*n* = 7), LPS (0127:B8, Difco Detroit, MI, USA) was infused intravenously at a rate of 250 ng/kg/min for 2 h, as previously described \[[@B14]\]. In the LPS plus carboxy-PTIO group (*n* = 7), 30 min after the start of LPS administration (250 ng/kg/min, for 2 h), carboxy-PTIO (Dojindo Laboratories, Kumamoto, Japan) was infused at a rate of 0.1 mg/kg/min for 1 h.

Sham protocol
-------------

In sham-shocked dogs, isotonic saline instead of LPS was infused for 2 h without (sham-vehicle group *n* = 3) and with carboxy-PTIO (sham-carboxy-PTIO group, *n* = 3) for 1 h.

Measurements of hemodynamic and blood gas parameters
----------------------------------------------------

Heart rate (HR), mean arterial pressure (MAP), mean pulmonary arterial pressure (MPAP), pulmonary capillary wedge pressure (PCWP), and central venous pressure (CVP), were measured at baseline, 0.5, 1, 2, 3, and 4 h. Cardiac output was simultaneously measured at baseline, 1,2,3, and 4 h using the thermodilution technique with a cardiac output computer (9520A, Baxter Healthcare Corp, Santa Ana, CA, USA); the mean value of two measurements and the cardiac index (CI) were both calculated. Arterial and mixed venous blood gases were measured at baseline, 1, 2, 3, and 4 h. Systemic vascular resistance index (SVRI), pulmonary vascular resistance index (PVRI), oxygen delivery index (DO~2~I), and oxygen consumption index (VO~2~I) were calculated using standard formulae.

Statistical analysis
--------------------

All data are presented as mean ± SEM. Parameters were compared over the study period using an analysis of variance for repeated measures. Where the F values was found to be significant, the data were compared with Turkey\'s test. Comparisons between the two groups at the same time point were analysed by one-way analysis of variance followed by Turkey\'s *post hoc* test when appropriate. *P* \< 0.05 was considered statistically significant.

Results
=======

Changes in hemodynamic parameters
---------------------------------

In both the sham-vehicle group and the sham-carboxy-PTIO group, no significant hemodynamic changes occurred during the 4 h period (Fig [1a](#F1){ref-type="fig"}, and Table [1](#T1){ref-type="table"}). In contrast, LPS administration caused a significant (*P* \< 0.01) decrease in MAP during the 1-4 h period, and carboxy-PTIO reversed the LPS-induced hypotension (Fig [1b](#F1){ref-type="fig"}). After LPS administration, CI tended to decrease although not to a statistically significant degree, and SVRI did not change during the 4 h period (Fig [1b](#F1){ref-type="fig"}). Other hemodynamic parameters (PVRI, MPAP, PCWP, CVP) did not change during the 4 h period (Table [2](#T2){ref-type="table"}).

Changes in blood gas parameters
-------------------------------

In both the sham-vehicle and the sham-carboxy-PTIO group, no appreciable changes in blood gas parameters (pH, PaO~2~, HCO~3~^-^, base excess) were observed during the 4 h period (Fig [2a](#F2){ref-type="fig"}). However, LPS administration caused metabolic acidosis and hypoxia, effects which were reversed by carboxy-PTIO (Fig [2b](#F2){ref-type="fig"}).

![Changes in mean arterial pressure (MAP), cardiac index (CI), and systemic vascular resistance index (SVRI) in anesthetized dogs after 2 h intravenous administration of **(a)** isotonic saline or **(b)** bacterial lipopolysaccharide (LPS: 250 ng/kg/min) with or without 1 h infusion of carboxy-PTIO (0.1 mg/kg/min). Each point represents the mean of sham-vehicle group (*n* = 3), sham-carboxy-PTIO group (*n* = 3), LPS group (*n* = 7), and LPS plus carboxy-PTIO group (*n* = 7); bar shows SEM. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01 *vs* baseline value. ^†^*P* \< 0.05; difference between the two groups at the same time point.](cc-1-1-045-1){#F1}

![Changes in arterial pH, PaO~2~, HCO~3~^-^, and base excess in anesthetized dogs after 2 h intravenous administration of **(a)** isotonic saline or **(b)** bacterial lipopolysaccharide (LPS: 250 ng/kg/min) with or without 1 h infusion or carboxy-PTIO (0.1 mg/kg/min). Each point represents the mean of sham-vehicle group (*n* = 3), sham-carboxy-PTIO group (*n* = 3), LPS group (*n* = 7), and LPS plus carboxy-PTIO group (*n* = 7); bar shows SEM. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01 vs baseline value.](cc-1-1-045-2){#F2}

Discussion
==========

This study clearly demonstrates that infusion of carboxy-PTIO prevents LPS-induced hypotension as well as metabolic acidosis and hypoxia in an endotoxin shock dog model. In the present study, LPS caused a rapid (within 1 h) and sustained fall in MAP over a 4 h period. This early decrease in MAP may be partly caused by immediate NO release due to activation of endothelial cNOS. In fact, in a study by Szabó *et al*, LPS-treated rats experienced early (within 1 h) hypotension which was prevented by L-NAME, but early hyporeactivity to noradrenaline was not inhibited by dexamethasone, which blocks the induction of iNOS \[[@B15]\], suggesting that the early hypotension is probably due to NO generated by the activation of cNOS. The same group has further suggested that the early NO-related vascular changes may be associated with the formation of peroxynitrite from endothelial cNOS-derived NO and superoxide \[[@B16]\]. Taken together, the mechanism of LPS-induced hypotension is more likely due to NO-induced peripheral vasodilation and vascular injury by peroxynitrite.

In our study, LPS-induced hypotension was accompanied by a tendency towards decreased CI during the 4 h period, suggesting that cardiac dysfunction may be a contributing factor. As a result, the calculated SVRI did not decrease despite peripheral vasodilation. The cause of this phenomenon may be explained by the method of fluid resuscitation chosen for this study. Although 10 ml/kg/h crystalloid solution was administered during the study period, this fluid resuscitation might not be sufficient to produce high cardiac output as usually observed during human septic shock.

Carboxy-PTIO directly scavenges NO without affecting NOS activity \[[@B17]\]. Therefore, the antihypotensive action of carboxy-PTIO is most likely mediated through its reaction with NO \[[@B12]\] to eliminate excess NO in septic shock animal models. It has previously been reported that infusion of carboxy-PTIO (0.056--1.7 mg/kg/min for 1 h) into LPS-induced septic shock rats dose-despondently prevented the decrease in MAP and improved survival rate \[[@B13]\]. Therefore, we chose a lower carboxy-PTIO dose (0.1 mg/kg/min for 1 h) for our dog model. Although blood carboxy-PTIO levels gradually decrease after discontinuing infusion \[[@B13]\], the LPS-induced hypotension was completely prevented by the smaller dose of carboxyl-PTIO used in our study. Thus, continuous infusion of carboxy-PTIO for 1 h seems enough to maintain the plasma at a level high enough to scavenge excess NO in the circulation.

Administration of carboxy-PTIO did not increase SVRI or decrease CI during the 4 h period in our septic shock dog model. These findings are in contrast to a marked decrease in CI associated with peripheral vasoconstriction by non-selective NOS inhibitors, such as L-NMMA, L-NNA, and L-NAME \[[@B6],[@B18],[@B19]\]. It has been demonstrated that L-NMMA caused a reduction in coronary flow associated with a decrease in cardiac output in isolated rat hearts, possibly as a result of myocardial ischemia \[[@B20]\]. By contrast, it has recently been reported that carboxy-PTI, a reaction product of carboxy-PTIO and NO, has a potent vasodilator effect in the canine coronary artery without altering systemic hemodynamic variables \[[@B21]\]. This effect may be responsible for the maintenance of cardiac output following carboxy-PTIO administration, and may also contribute to the maintenance adequate regional blood flow.

It has been shown that the hemodynamic effect of carboxy-PTIO is minimal in normal rats \[[@B13]\]. This finding was confirmed in our control dogs. This is in marked contrast to the potent peripheral vasoconstriction by non-selective NOS inhibitors \[[@B5],[@B7]\]. The marked increase in systemic blood pressure brought about by well known NOS inhibitors, such as L-NMMA and L-NNA, is due to the complete inhibition of endothelial cNOS. Since NO generated by endothelial cNOS plays vital roles in maintaining organ blood flow due to its vasodilator and antiplatelet aggregation effects, the complete blockade of endothelial cNOS by non-selective NOS inhibitors during septic shock should lead to a marked decrease in organ blood flow and ischemia.

Administration of non-selective NOS inhibitors in septic shock models has been shown to deteriorate metabolic acidosis \[[@B7]\], reduce liver perfusion and induce liver injury \[[@B5],[@B22]\]. In contrast, a recent study from our laboratory has revealed that in LPS-treated rabbits carboxy-PTIO preserved liver energetics, alleviated hepatocellular acidosis, normalized various hydrophilic metabolites such as lactate and alanine in the liver, and decreased plasma concentrations of lactate and pyruvate \[[@B23]\]. These findings suggest that carboxy-PTIO improves hepatocellular metabolic derangement in endotoxin shock models. In this study carboxy-PTIO prevented LPS-induced metabolic acidosis and hypoxia in a dog model, although lactate and hepatic transaminases were not determined. It seems most likely that the marked improvement in metabolic acidosis and hypoxia in septic shock is due to the maintenance of adequate organ perfusion and oxygen delivery by carboxy-PTIO.

However, a major drawback of carboxy-PTIO for its potential use in septic shock is its inactivation by endogenous reducing substances. For example, ascorbic acid has been shown to reduce carboxy-PTIO to a non-radical N-hydroxy derivative, which can no longer scavenge NO \[[@B13]\]. To overcome such fast reduction of nitronyl-nitroxyl radicals, attempts have been made to incorporate nitronyl nitroxide into unilamellar phosphatidylcholine liposomes \[[@B24]\].

It should be noted that hemoglobin may also be used in septic shock models and is as effective an NO scavenger as carboxy-PTIO. It has recently been shown that administration of cross-linked human hemoglobin in a septic pig model improved MAP, but exacerbated pulmonary hypertension and hypoxia \[[@B25]\]. Furthermore, it has been reported that administration of stroma-free soluble hemoglobin worsened hypoxia and acidosis in a septic dog model \[[@B26]\]. Therefore, the therapeutic potential of hemoglobin as an NO scavenger in patients with sepsis appears to be more limited than that of carboxy-PTIO.

In conclusion, our results show that carboxy-PTIO improves blood pressure, metabolic acidosis, and hypoxia in septic shock dogs through scavenging excess NO induced by LPS. Since such NO scavengers preferentially quench the biological action of excess NO without affecting NOS activity, they may represent a promising approach to the treatment of human septic shock. Further studies are needed to design and develop more potent and long-lived nitronyl nitroxide compounds.

###### 

Hemodynamic and gas exchange parameters in anesthetized dogs after isotonic saline infusion with or without carboxy-PTIO

                                                                            Hours                   
  ------------------------ -------------- ---------- ---------- ----------- ----------- ----------- ----------
  HR (beats/min)           Saline         145 ± 18   135 ± 18   128 ± 23    133 ± 18    143 ± 13    152 ± 15
                           Carboxy-PTIO   152 ± 14   153 ± 14   150 ± 11    157 ± 11    151 ± 8     155 ± 9
  MPAP (mmHg)              Saline         15 ± 2     15 ± 2     15 ± 2      15 ± 2      16 ± 1      16 ± 0
                           Carboxy-PTIO   16 ± 2     16 ± 1     15 ± 1      15 ± 1      16 ± 2      17 ± 2
  PCWP (mmHg)              Saline         7 ± 2      7 ± 2      6 ± 2       8 ± 3       7 ± 3       5 ± 1
                           Carboxy-PTIO   7 ± 1      7 ± 1      7 ± 1       8 ± 1       8 ± 1       8 ± 1
  CVP (mmHg)               Saline         4± 1       5 ± 0      5 ± 1       4 ± 1       4 ± 1       5 ± 0
                           Carboxy-PTIO   5 ± 1      5 ± 1      5 ± 1       5 ± 1       5 ± 1       5 ± 1
  PVRI (dyn s/cm^5^m^2^)   Saline         168 ± 5    \-         176 ± 32    186 ± 27    214 ± 51    225 ± 57
                           Carboxy-PTIO   163 ± 10   \-         164 ± 21    168 ± 17    175 ± 31    199 ± 31
  DO~2~I (ml min/m^2^)     Saline         701 ± 91   \-         636 ± 122   608 ± 108   633 ± 103   632 ± 85
                           Carboxy-PTIO   705 ± 97   \-         647 ± 78    535 ± 26    553 ± 12    575 ± 30
  VO~2~I (ml min/m^2^)     Saline         112 ± 7    \-         116 ± 6     118 ± 11    121 ± 10    123 ± 9
                           Carboxy-PTIO   103 ± 8    \-         114 ± 14    120 ± 3     132 ± 7     137 ± 8

Values are mean ± SEM (*n* = 3). HR=heart rate; MPAP = mean pulmonary arterial pressure; PCWP = pulmonary capillary wedge pressure; CVP = central venous pressure; PVRI = pulmonary vascular resistance index; DO~2~I = O~2~ delivery index; VO~2~I, = O~2~ consumption index;- = not measured.

###### 

Hemodynamic and gas exchange parameters in anesthetized dogs after intravenous administration of bacterial lipopolysaccharide with or without carboxy-PTIO

                                                                           Hours                 
  ------------------------ -------------- ---------- ---------- ---------- ---------- ---------- ----------
  HR (beats/min)           LPS            143 ± 18   144 ± 8    150 ± 11   152 ± 6    157 ± 8    155 ± 10
                           Carboxy-PTIO   144 ± 13   147 ± 12   154 ± 12   156 ± 11   155 ± 11   158 ± 12
  MPAP (mmHg)              LPS            17 ± 13    17 ± 13    16 ± 13    18 ± 4     18 ± 4     19 ± 5
                           Carboxy-PTIO   16 ± 1     16 ± 1     16 ± 1     17 ± 1     17 ± 1     17 ± 1
  PCWP (mmHg)              LPS            8 ± 2      7 ± 1      7 ± 2      7 ± 2      7 ± 2      8 ± 2
                           Carboxy-PTIO   8 ± 1      8 ± 1      8 ± 1      8 ± 1      9 ± 1      9 ± 1
  CVP (mmHg)               LPS            4 ± 1      4 ± 1      3 ± 1      3 ± 1      4 ± 1      5 ± 1
                           Carboxy-PTIO   4 ± 1      3 ± 1      4 ± 1      4 ± 1      5 ± 1      4 ± 1
  PVRI (dyn s/cm^5^m^2^)   LPS            180 ± 22   \-         201 ± 17   270 ± 34   229 ± 35   252 ± 51
                           Carboxy-PTIO   157 ± 13   \-         168 ± 11   177 ± 17   208 ± 17   229 ± 27
  DO~2~I (ml min/m^2^)     LPS            592 ± 59   \-         538 ± 49   438 ± 43   482 ± 44   439 ± 35
                           Carboxy-PTIO   722 ± 83   \-         725 ± 65   679 ± 64   616 ± 58   558 ± 50
  VO~2~I (ml min/m^2^)     LPS            128 ± 17   \-         115 ± 12   117 ± 14   127 ± 18   124 ± 12
                           Carboxy-PTIO   125 ± 12   \-         123 ± 12   120 ± 13   123 ± 16   130 ± 17

Values are mean ± SEM (*n* = 7). LPS = lipopolysaccharide; HR = heart rate; MPAP = mean pulmonary arterial pressure; PCWP = pulmonary capillary wedge pressure; CVP = central venous pressure; PVRI = pulmonary vascular resistance index; DO~2~I = O~2~ delivery index; VO~2~I = O~2~ consumption index;- = not measured.
